US will retaliate if India does not supply drugs needed to fight coronavirus: Donald Trump

Prashasti Awasthi Mumbai | Updated on April 07, 2020 Published on April 07, 2020

US President Donald Trump (file photo)   -  Bloomberg

Dropping hints that the United States will maintain a strict stance on India if it does not release the hydroxychloroquine, US President Donald Trump remarked: “I spoke to him (PM Modi), Sunday morning and I said we appreciate it that you are allowing our supply (of Hydroxychloroquine) to come out, if he doesn't allow it to come out, that would be okay, but of course, there may be retaliation, why wouldn't there be?”, as per media reports.

Trump’s comments came days after India denied the supply of hydroxychloroquine, a drug seen as the key to cure coronavirus.

India had earlier banned the drug’s export “without any exceptions,” India’s Directorate General of Foreign Trade had said in an April 4 order on its website.

After getting to know of India’s decision, Trump had called Modi on April 4 and asked him to allow the export of hydroxychloroquine to the US to use it against the coronavirus epidemic.

Modi had tweeted after the call that they "agreed to deploy the full strength of the India-US partnership to fight Covid-19".

On April 6, India decided to allow the supply of hydroxychloroquine on a “case-by-case” basis. It also allowed the export of paracetamol, a popular antipyretic, as well as some more drugs.

Trump is promoting the use of hydroxychloroquine as a treatment and preventive for Covid-19. The medicine is used to treat malaria and lupus and trials are underway in New York to test its efficacy against coronavirus.

The US is witnessing the peak of the pandemic and is believed to be the next hotspot of the Covid-19 outbreak. The number of cases in the US has surpassed three lakh mark and with over 10,000 died due to the deadly virus.

Donald Trump had warned America to brace for a “very, very painful two weeks” as the White House projected that the coronavirus pandemic could claim 100,000 to 240,000 lives, even if current social distancing guidelines are maintained, the Guardian reported.

Published on April 07, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.